Related Experiment Videos
Hemostatic molecular markers in nephrotic syndrome
T Y Chen1, C C Huang, C J Tsao
1Section of Hematology, National Cheng-Kung University, Tainan, Taiwan, R.O.C.
American Journal of Hematology
|December 1, 1993
Summary
Nephrotic syndrome patients show activated hemostasis markers, including fibrinopeptide A (FPA), thrombin-antithrombin III complex (TAT), and fragment F1 + 2 (F1 + 2). Low antithrombin III levels may result from urinary loss and consumption.
Area of Science:
- Nephrology
- Hematology
- Clinical Chemistry
Background:
- Nephrotic syndrome is associated with an increased risk of thromboembolic events.
- Understanding hemostatic changes is crucial for managing patients with nephrotic syndrome.
Purpose of the Study:
- To quantitatively assess hemostatic molecular markers in patients with nephrotic syndrome.
- To investigate the activation of coagulation pathways in nephrotic syndrome.
Main Methods:
- Enzyme immunoassay was used to measure plasma levels of fibrinopeptide A (FPA), thrombin-antithrombin III complex (TAT), and fragment F1 + 2 (F1 + 2).
- Measurements were performed in 21 patients with nephrotic syndrome and 16 healthy controls.
Main Results:
- Significantly elevated levels of FPA (17.5 vs 4.5 ng/ml), F1 + 2 (1.4 vs 0.5 ng/ml), and TAT (1.0 vs 0.2 microgram/l) were observed in nephrotic patients compared to controls (P < 0.02, P < 0.001, P < 0.05, respectively).
- These findings indicate activation of intravascular hemostasis in nephrotic syndrome.
Conclusions:
- Patients with nephrotic syndrome exhibit evidence of intravascular coagulation activation.
- Low antithrombin III levels in nephrotic syndrome may be attributed to both urinary losses and increased consumption during coagulation.